<DOC>
	<DOCNO>NCT00287976</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well irinotecan work treat young patient refractory recurrent hepatoblastoma .</brief_summary>
	<brief_title>Irinotecan Treating Young Patients With Refractory Recurrent Hepatoblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine biological activity irinotecan hydrochloride , give prolonged schedule , term response rate rate early progression , young patient refractory recurrent hepatoblastoma . Secondary - Determine duration response patient show stable disease objective response ( partial complete response ) drug . - Determine time progression overall survival patient treated drug . - Determine rate resectability patient treat drug . - Determine toxicity drug patient . OUTLINE : This multicenter study . Patients receive irinotecan IV 1 hour day 1-5 8-12 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients undergo evaluation tumor resectability course 2 , 3 , 4 . Patients whose disease consider resectable time point proceed surgery . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Hepatoblastoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hepatoblastoma Refractory recurrent disease Failed prior firstline secondline treatment Metastatic disease allow Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Elevated serum alphafetoprotein ( AFP ) allow No hepatocellular carcinoma PATIENT CHARACTERISTICS : Lansky performance status 50100 % patient ≤ 10 year age OR Karnofsky performance status 50100 % patient &gt; 10 year age Life expectancy &gt; 8 week Hemoglobin &gt; 8 g/dL Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm^3 Serum bilirubin ≤ 2 time normal AST/ALT ≤ 2 time normal Serum creatinine ≤ 3 time normal Normal metabolic parameter ( i.e. , serum electrolyte , glucose , calcium , phosphate ) Not pregnant nursing No severe uncontrolled infection enterocolitis PRIOR CONCURRENT THERAPY : Recovered toxicity prior therapy No chemotherapy within 3 week prior study entry No prior irinotecan No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>childhood hepatoblastoma</keyword>
	<keyword>recurrent childhood liver cancer</keyword>
</DOC>